Valuation: GlaxoSmithKline Pakistan Limited

Market Cap 99.51B 360M 320M 296M 270M 509M 34.13B 517M 3.56B 1.4B 17.81B 1.35B 1.32B 56.78B P/E 2026 *
9.41x
P/E 2027 * 7.82x
Enterprise Value 99.51B 360M 320M 296M 270M 509M 34.13B 517M 3.56B 1.4B 17.81B 1.35B 1.32B 56.78B EV / Sales 2026 *
1.45x
EV / Sales 2027 * 1.33x
Free-Float
16.89%
Yield 2026 *
5.77%
Yield 2027 * 6.66%
09-03 GlaxoSmithKline Pakistan Limited Announces Appointment of Muhammad Yousuf Vohra as Chief Financial Officer, Effective October 15, 2026 CI
09-03 GlaxoSmithKline Pakistan Limited Announces Appointment of Muhammad Yousuf Vohra as Finance Director, Effective October 15, 2026 CI
08-28 GlaxoSmithKline Pakistan Limited Announces Appointment of Muhammad Masood Ahmed Khan to Executive Director, Effective August 28, 2026 CI
08-25 GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
08-25 GlaxoSmithKline Pakistan Limited Interim Cash Dividend for the Half Year Ended June 30, 2026, Payable on September 11, 2026 CI
08-03 GlaxoSmithKline Pakistan Limited Appoints Umair Majeed as Interim/Acting Chief Financial Officer, Effective from July 30, 2026 CI
08-03 GlaxoSmithKline Pakistan Limited Announces Appointment of Hasham Ali Baber as Non-Executive Director, Effective July 30, 2026 CI
06-08 GlaxoSmithKline Pakistan Limited Announces Resignation of Hasham Baber as Chief Financial Officer, Effective June 30, 2026 CI
06-08 GlaxoSmithKline Pakistan Limited Announces Resignation of Hasham Baber as Executive Director of the Board of Directors, Effective June 30, 2026 CI
06-01 GlaxoSmithKline Pakistan Limited Announces Resignation of Ana Paula De Freitas Passos as Non-Executive Director, Effective May 31, 2026 CI
04-30 GlaxoSmithkline Pakistan Limited Approves Final Cash Dividend for the Year Ended 31 December, 2025 CI
04-30 GlaxoSmithkline Pakistan Limited Approves Board Elections, Effective May 25, 2026 CI
04-27 GlaxoSmithKline Pakistan Limited Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
1 day+0.19%
1 week-1.31%
Current month-0.16%
1 month-2.66%
3 months-12.66%
6 months-20.60%
Current year-19.84%
1 week 309
Extreme 309
315.99
1 month 305
Extreme 305
326.05
Current year 293.09
Extreme 293.09
459.27
1 year 293.09
Extreme 293.09
459.27
3 years 74
Extreme 74
481
5 years 68
Extreme 68
481
10 years 68
Extreme 68
481
Manager TitleAgeSince
Chief Executive Officer - 01/03/2020
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member - 07/05/2011
Director/Board Member - 05/12/2018
Director/Board Member 72 02/04/2020
Change 5-day change 1-year change 3-year change Capi.($)
+0.19%-1.31%-27.05%+312.20% 360M
+0.43%+6.59%+56.57%+107.01% 1,120B
+0.90%-2.25%+32.26%+67.33% 616B
+0.71%+3.24%+24.33%+91.20% 504B
-0.13%+5.98%+33.66%+52.01% 367B
+0.52%+0.24%+72.13%+43.10% 360B
-0.95%+4.70%+19.65%+43.09% 288B
-1.98%+3.73%-0.89%+17.28% 258B
-0.35%+4.25%+44.74%+52.51% 234B
-0.75%+3.32%+27.18%+96.05% 194B
Average -0.14%+2.99%+28.26%+88.18% 394.13B
Weighted average by Cap. +0.13%+3.52%+39.33%+73.54%

Financials

2026 *2027 *
Net sales 68.81B 249M 221M 205M 186M 352M 23.6B 357M 2.46B 966M 12.32B 933M 913M 39.26B 74.58B 270M 240M 222M 202M 381M 25.58B 387M 2.67B 1.05B 13.35B 1.01B 990M 42.55B
Net income 10.49B 37.91M 33.7M 31.23M 28.42M 53.63M 3.6B 54.49M 375M 147M 1.88B 142M 139M 5.99B 12.42B 44.89M 39.9M 36.98M 33.65M 63.49M 4.26B 64.51M 445M 174M 2.22B 168M 165M 7.09B
Net Debt - -
Projected Income Statement - Annual - GlaxoSmithKline Pakistan Limited
Logo GlaxoSmithKline Pakistan Limited
GlaxoSmithKline Pakistan Limited is a Pakistan-based global biopharma company. The Company is engaged in the manufacturing and marketing of research-based specialties and pharmaceutical products. It caters to therapy areas, such as anti-infectives, dermatology, respiratory, analgesics, urology, and vaccines. Its pharmaceutical brands include Augmentin, Velosef, Amoxil, Dermovate, Clobevate, Betnovate, Calpol and Ventolin. Its portfolio has three product areas: vaccines, specialty, and general medicines. Its Amoxil branded products are an antibiotic indicated for the treatment of upper respiratory tract infections and helicobacter pylori. Its Vates portfolio comprises brands, such as Dermovate, Clobevate, Cutivate, and Betnovate. Its Vates portfolio addresses to a broad category of steroid responsive dermatoses indications, contact, and other kinds of dermatitis. Its Calpol branded products are used for treatment of mild to moderate fever and pain.
Employees
1,606
Date Price Change Volume
16/10/26 PKR 312.45 +0.19% 13,698
15/10/26 PKR 311.85 -0.19% 82,470
14/10/26 PKR 312.44 +0.40% 57,509
13/10/26 PKR 311.19 -0.26% 62,009
12/10/26 PKR 312.00 -1.45% 63,979
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
312.45PKR
Average target price
510.00PKR
Spread / Average Target
+63.23%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - GlaxoSmithKline Pakistan Limited
  1. Stock Market
  2. Stocks
  3. GLAXO Stock